Nexalin Technology (NXL) announced the appointment of Dr. Robert Rothstein to its Scientific Advisory Board. In anticipation of the Company’s new FDA submissions, Dr. Rothstein will support Nexalin’s preparation of its Q-submission for a meeting with the FDA later this year. Dr. Rothstein has served in senior roles at prestigious institutions including the University of Chicago, Harbor/UCLA Medical Center, and Suburban Hospital/Johns Hopkins Medicine.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NXL:
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- 3 Penny Stocks to Watch Now, 10/9/25
- Why Is Nexalin Technology Stock (NXL) Down 20% Today?
- Nexalin Technology announces additional results in AD with Gen-2 SYNC device
- Nexalin Technology announces issuance of U.S. patent covering HALO Clarity